Pharmaceutical

Enzalutamide by Pfizer for Fallopian Tube Cancer: Likelihood of Approval

Enzalutamide is under clinical development by Pfizer and currently in Phase II for Fallopian Tube Cancer.

Dec 24, 2023 - 18:00
Enzalutamide is under clinical development by Pfizer and currently in Phase II for Fallopian Tube Cancer.
Read the original article

Tags:

Previous Article

Enzalutamide by Pfizer for Peritoneal Cancer: Likelihood of Approval

Next Article

Devimistat by Cornerstone Pharmaceuticals for Soft Tissue Sarcoma: Likelihood of...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

“The innovation just explodes”: The role of AI in accelerating biopharma R&D

“The innovation just explodes”: The role of AI in accel...

Jul 25, 2023

Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound

Eli Lilly gets FDA approval to sell Mounjaro as obesity...

Nov 9, 2023

Pfizer and BioNTech’s Covid-19/flu combination vaccine falters in Phase III readout

Pfizer and BioNTech’s Covid-19/flu combination vaccine ...

Aug 17, 2024